We are delighted to announce our official Scientific Advisory Board for this year’s event.

 

The European Stem Cells & Regenerative Medicine congress was developed with input from a team of internationally recognised professionals in the stem cell, regenerative medicine and tissue engineering community. Terrapinn would like to thank the following members of the scientific advisory board for help in creating this congress.

 

Scientific Board Members include:

There are still opportunities for you to join our official scientific advisory board. To apply please email neil.darkes@terrapinn.com

 

 

Chris Mason PhD FRCS
Director, Regenerative Medicine Bioprocessing Unit
University College London

Chris is at the forefront of the emerging field of regenerative medicine bioprocessing plus is involved in a number of committees, working groups and initiatives related to both the academic and commercial advancement of stem cells and tissue engineering. Originally graduating from Imperial College (Molecular Biology) and St. Thomas’s Hospital Medical School (Medicine) and then specialising in surgery - Fellow of the Royal College of Surgeons. In addition, Chris has a PhD in Biochemical Engineering (UCL), leads the Regenerative Medicine Bioprocess Group at UCL and has broad range of expertise in industrial consultancy. Furthermore, Chris has over ten years experience at boardroom level of running technology companies and is co-organiser of the London Regenerative Medicine Network.

 

Stephen L Minger PhD
Director, Stem Cell Biology Laboratory, Wolfson Centre for Age-Related Diseases
King’s College London

 

Dr Stephen Minger is the Director of the Stem Cell Biology Laboratory and a Senior Lecturer in the new Wolfson Centre for Age Related Diseases at King's College London.  Dr Minger received his PhD in Pathology (Neurosciences) in 1992 from the Albert Einstein College of Medicine. From 1992-1994, he was a post-doctoral fellow in the laboratory of Professor Fred Gage, University of California, San Diego, where he first began to pursue research in neural stem cell biology. Additional post-doctoral training was obtained at the University of Kentucky, and in 1995, Dr Minger was appointed an Assistant Professor in Neurology at The University of Kentucky Medical School. He moved his stem cell research programme to Guy’s Hospital in 1996 and was appointed a Lecturer in Biomolecular Sciences at King's College London in 1998. Over the last 13 years, his research group has worked with a wide range of somatic stem cell populations, as well as mouse and human embryonic stem (ES) cells. In 2002, together with Dr Susan Pickering and Professor Peter Braude, Dr Minger was awarded one of the first two licenses granted by the UK Human Fertilisation and Embryology Authority for the derivation of human ES cells. His group subsequently generated the first human embryonic stem cell line in the UK and was one of the first groups to deposit this into the UK Stem Cell Bank.  They have gone on to generate three new human ES cell lines, including one that encodes the most common genetic mutation resulting in Cystic Fibrosis. 

 

Dr Minger has established highly productive collaborations with a number of specialist groups in many areas of clinical interest throughout the UK, and is one of the co-organisers of the London Regenerative Medicine Network, a grass-roots, research-led organisation designed to stimulate clinical translation of cell- and gene-based therapies within London.  

Dr Minger’s research is supported by the UK Medical Research Council, The Juvenile Diabetes Research Foundation International, The Oliver Bird Foundation, The Wellcome Trust, The UK Department of Trade and Industry, The Charitable Foundation of Guy’s and St Thomas’ Hospitals, the BBSRC, and the EPSRC amongst others. 

 

Hugh Ilyine,
Vice President and Chief Operating Officer,
Stem Cell Sciences

Hugh Ilyine joined the company in 2000 and brought an extensive national and international experience in developing, registering, manufacturing and distributing products in the agrochemical and bioscience sector. More recently, he was General Manager for the Bioscience Division of Bonlac Foods Ltd. Prior to this, Hugh Ilyine had ten years of managing director and international product management experience with the Rhone-Poulenc Agrochimie [S.A.]. In his current role, Hugh Ilyine oversees the local and international business operations of Stem Cell Sciences.

 

Dr Tim Allsopp,
Chief Scientific Officer,
Stem Cell Sciences

Dr. T. E. Allsopp has 14 years combined experience as a cell & molecular biologist, with particular interest in neurobiology. Published papers include the topics of neural cell fate specification, programmed cell death regulation in the nervous system and acute, chronic nervous system disease. After 12 years as a leading academic with a developing interest in the biology of stem cells he joined Stem Cell Sciences Ltd to utilize pluripotent, embryonic stem cells to discover unique human disease treatment and cures. As a senior scientist with SCS Ltd, he has gained valuable research experience in the basic biology, growth, regulated differentiation, engineering & technology application of murine embryonic stem cells (ES cells). A combination of industrial sponsored academic research & biotech experience have also provided a detailed knowledge base that facilitates the current commercial exploitation of stem cell technology in pharmaceutical R&D. Current responsibilities include directing the research in ES biology, development of ES-based technologies for applications in gene & drug discovery and business development.